Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
Autor: | König, D, Schär, S, Vuong, Diem, Guckenberger, Matthias, Furrer, K, Opitz, I, Weder, W, Rothschild, S I, Ochsenbein, A, Zippelius, A, Addeo, A, Mark, M, Eboulet, E I, Hayoz, S, Thierstein, S, Betticher, D C, Ris, H-B, Stupp, R, Curioni-Fontecedro, A, Peters, S, Pless, M, Früh, M |
---|---|
Přispěvatelé: | University of Zurich, König, D |
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494 |
DOI: | 10.5167/uzh-220870 |
Databáze: | OpenAIRE |
Externí odkaz: |